UK's GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion
British drugmaker GSK on Tuesday agreed to acquire U.S.-listed cancer drug developer Nuvalent for $10.6 billion to boost its lung cancer portfolio.
More info
